TOP TEN perturbations for 1553568_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553568_a_at
Selected probe(set): 1553568_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553568_a_at (1553568_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

paracetamol (acetaminophen) study 5 (5000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.5192604
Number of Samples:2 / 2
Experimental paracetamol (acetaminophen) study 5 (5000uM)
Hepatocytes treated with compound: acetaminophen (5000uM; CHEMBL112) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

methylprednisolone; immunoglobulin (IVIG) study 1 / Kawasaki disease study 2 (non-responder)

Relative Expression (log2-ratio):-1.9021769
Number of Samples:4 / 10
Experimental methylprednisolone; immunoglobulin (IVIG) study 1
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after combined treatment with intravenous methylprednisolone (30mg/kg/2h) followed by intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to simple IVIG therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients exhibited good response to the combined therapy. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:, ,
Control Kawasaki disease study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)

Relative Expression (log2-ratio):-1.6707516
Number of Samples:4 / 4
Experimental immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

colchicine study 6 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):1.5218449
Number of Samples:2 / 2
Experimental colchicine study 6 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-1.4751911
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

theophylline study 4 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):1.4707794
Number of Samples:2 / 2
Experimental theophylline study 4 (10000uM)
Hepatocytes treated with compound: theophylline (10000uM; CHEMBL190) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

theophylline study 5 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):1.3403053
Number of Samples:2 / 2
Experimental theophylline study 5 (10000uM)
Hepatocytes treated with compound: theophylline (10000uM; CHEMBL190) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

paracetamol (acetaminophen) study 4 (5000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):1.3339319
Number of Samples:2 / 2
Experimental paracetamol (acetaminophen) study 4 (5000uM)
Hepatocytes treated with compound: acetaminophen (5000uM; CHEMBL112) for 2 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 2 hours.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-1.2998466
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):1.2899399
Number of Samples:4 / 4
Experimental cicloheximide study 1
MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:---
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.